GGrantIndex
← Leaderboards

Jodi L. McBride

University Of Iowa

$4,533,005
Attributed
$4,533,005
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200720
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$4,533,005 · 7

By mechanism

R01$3,100,703 · 1
R00$729,861 · 1
R21$437,500 · 1
F32$95,066 · 1
K99$89,942 · 1
P51$79,933 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Huntington Disease

Research focus

Huntington DiseaseCorpus Striatum StructureBehavioralNeurodegenerative DisordersGenesMotorGain Of FunctionCag RepeatMutantAffectBrainIn VivoMolecularMacaca MulattaCognitiveBrain RegionInjection Of Therapeutic AgentNeuropathologyGlutamineNonhuman PrimateAreaPathologyNerve DegenerationPutamen

Grant awards (14)

Cortico-basal ganglia connectivity in a non-human primate model of Huntington's disease$530,054
R01 · FY2020 · NS · contact PI
Cortico-basal ganglia connectivity in a non-human primate model of Huntington's disease$581,459
R01 · FY2019 · NS · contact PI
Cortico-basal ganglia connectivity in a non-human primate model of Huntington's disease$631,913
R01 · FY2018 · NS · contact PI
Cortico-basal ganglia connectivity in a non-human primate model of Huntington's disease$644,404
R01 · FY2017 · NS · contact PI
Cortico-basal ganglia connectivity in a non-human primate model of Huntington's disease$712,873
R01 · FY2016 · NS · contact PI
Global RNA Interference Therapy for Huntingtons Disease$437,500
R21 · FY2016 · NS · contact PI
RNAi therapy for Huntingtons disease: safety & efficacy in the nonhuman primate$234,718
R00 · FY2013 · NS · contact PI
RNAi therapy for Huntingtons disease: safety & efficacy in the nonhuman primate$246,143
R00 · FY2012 · NS · contact PI
RNAi therapy for Huntingtons disease: safety & efficacy in the nonhuman primate$249,000
R00 · FY2011 · NS · contact PI
RNAI THERAPY FOR HUNTINGTONS DISEASE: SAFEY & EFFICACY IN THE NONHUMAN PRIMATE$43,647
P51 · FY2011 · RR · contact PI
SYSTEMIC DELIVERY RNA INTERFERENCE USING AAV9; TREAT HUNTINGTON'S DISEASE$36,286
P51 · FY2011 · RR · contact PI
RNAi therapy for Huntingtons disease: safety & efficacy in the nonhuman primate$89,942
K99 · FY2010 · NS · contact PI
Non-alledle specific RNAi as a potential therapy for Huntington's disease$49,646
F32 · FY2008 · NS · contact PI
Non-alledle specific RNAi as a potential therapy for Huntington's disease$45,420
F32 · FY2007 · NS · contact PI